INTRODUCTION {#rjx071s1}
============

Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal dominant tumor syndrome arising from mutations of the MEN 1 tumor suppressor gene on chromosome 11q13 \[[@rjx071C1]\]. It is characterized by primary hyperparathyroidism, enteropancreatic neuroendocrine neoplasia and pituitary neoplasia \[[@rjx071C1]\].

Thymic epithelial tumors are less common (1--5%) manifestations of MEN 1 \[[@rjx071C2]\]. Furthermore, majority of these thymic epithelial tumors are thymic carcinoids and thymoma patients in MEN 1 is rare. Only four cases of thymoma with MEN 1 were found when we performed a literature search using PubMed \[[@rjx071C3]--[@rjx071C6]\].

Although thymic carcinomas often contain tumor cells having a neuroendocrine feature, thymomas with neuroendocrine differentiation are extremely rare \[[@rjx071C7], [@rjx071C8]\].

Herein, we report a case of thymoma (World Health Organization \[WHO\] type B3) with neuroendocrine differentiation in MEN 1.

CASE REPORT {#rjx071s2}
===========

A 68-year-old man, who was already diagnosed as MEN 1 previously, was admitted to our hospital with gradually progressive muscle weakness. The physician thought the disease of this patient might be a paraneoplastic syndrome. Therefore, systemic radiological examination was performed. Enhanced computed tomography (CT) and magnetic resonance imaging (MRI) of the chest revealed an anterior mediastinal tumor (Figs. [1](#rjx071F1){ref-type="fig"}A and B) and no other tumorous lesions were found. The lesion was highly suspected to be thymic epithelial tumor radiologically. Figure 1:Enhanced CT (**A**) and MRI (**B**) of the chest revealed an anterior mediastinal tumor.

Surgical exploration was performed through a video-assisted thoracoscopic surgery under general anesthesia. No tumor invasion to the pericardium and lung was found. The tumor was smoothly removed. Post-operative course was uneventful.

Histologically, the tumor cells show round to oval, hyperchromatic nuclei and the nucleoli of the tumor cells are inconspicuous. They proliferate with a solid nest-like pattern, and Hassall\'s bodies, vague individual keratinization and psammoma bodies and coarse calcification are seen in the center portion of the tumor nests (Fig. [2](#rjx071F2){ref-type="fig"}). Convincing findings of thymic carcinoid could not be identified. On immunohistochemical stain, the tumor cells were strong positive for synaptophysin (Fig. [3](#rjx071F3){ref-type="fig"}A), positive for chromogranin (Fig. [3](#rjx071F3){ref-type="fig"}B) and CD56 (Fig. [3](#rjx071F3){ref-type="fig"}C). Taken together, pathologists diagnosed of thymoma (WHO type B3, Masaoka stage I) with neuroendocrine differentiation combined with MEN 1. Figure 2:Histological findings of the tumor. Hematoxylin and eosin staining.Figure 3:Immunohistochemical findings of the tumor for synaptophysin (**A**), chromogranin (**B**) and CD56 (**C**).

After surgery, his symptom (progressive muscle weakness) unchanged and he was diagnosed as amyotrophic lateral sclerosis. At six post-operative months, there was no evidence of local recurrence or distant metastasis.

DISCUSSION {#rjx071s3}
==========

The present case had two rare characteristics. First, majority of thymic epithelial tumors in MEN 1 are thymic carcinoids and patients with thymoma in MEN 1 is rare \[[@rjx071C3]--[@rjx071C6]\]. Second, thymomas with neuroendocrine differentiation are extremely rare \[[@rjx071C7], [@rjx071C8]\]. To the best of our knowledge, this is the first such case ever reported.

Only four cases of thymoma in MEN 1 was previously reported \[[@rjx071C3]--[@rjx071C6]\]. Miller *et al*. \[[@rjx071C3]\] reported a case of synchronous thymoma (type B3) and thymic carcinoid in a woman with MEN 1. Kojima *et al*. \[[@rjx071C4]\] reported a mixed-type invasive thymoma (WHO histological type was not available) with MEN 1. De Toma *et al*. \[[@rjx071C5]\] reported a thymoma (type B1) in MEN 1. Vroegindeweij-Claessens *et al*. \[[@rjx071C6]\] reported a case of myasthenia gravis and thymoma (WHO histological type was not available) in MEN 1. Vroegindeweij-Claessens *et al*. \[[@rjx071C6]\] discussed that the association of tumor of the thymus and parathyroid gland is not surprising as these structures have a common embryonic origin from the third pharyngeal pouch. This discussion is helpful to understand the association between thymic epithelial tumor and MEN 1. Lim *et al*. \[[@rjx071C10]\] examined possible genotype--phenotype correlation in thymic carcinoid from MEN 1 and reported a high prevalence of truncating MEN 1 mutation in patients with thymic carcinoid. This might be a pathways of tumorigenesis of thymic carcinoids in MEN 1 at least in part. However, it has been still unknown why thymoma in MEN 1 is rare.

The neuroendocrine differentiation of thymomas is extremely rare \[[@rjx071C7], [@rjx071C8]\]. None of previously reported four thymomas in MEN 1 \[[@rjx071C3]--[@rjx071C6]\] showed neuroendocrine differentiation. It has been accepted that thymic carcinomas often exhibit neuroendocrine differentiation \[[@rjx071C9]\]. However, reports of thymomas with neuroendocrine differentiation have been extremely rare \[[@rjx071C7], [@rjx071C8]\]. The present case is a first case of thymoma with neuroendocrine differentiation in MEN 1. Shiraishi *et al*. \[[@rjx071C7]\] reported a case of thymoma (type B3) with neuroendocrine differentiation. Park *et al*. \[[@rjx071C8]\] also reported an atypical thymoma (type B3) with neuroendocrine differentiation combined with hyperparathyroidism. Although their case did not fulfill the diagnostic criteria of MEN 1, their case might have a similar genetic background with the present case.

It has been reported that MEN 1-related thymic carcinoids carry an ominous prognosis due to their aggressive nature and potential for metastasis, and they are associated with increased mortality in patients with MEN 1 \[[@rjx071C11]\]. To date, it is unclear whether neuroendocrine differentiation itself is associated with increased malignancy in thymic epithelial tumors. Further, long-term follow-up of thymomas with neuroendocrine differentiation will be necessary.
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